Implementation of Oral and Extended-Release Naltrexone for the Treatment of Emergency Department Patients With Moderate to Severe Alcohol Use Disorder: Feasibility and Initial Outcomes

被引:15
|
作者
Anderson, Erik S. [1 ,2 ]
Chamberlin, Mac [1 ]
Zuluaga, Marisa [1 ]
Ullal, Monish [2 ,3 ]
Hawk, Kathryn [4 ]
McCormack, Ryan [5 ]
D'Onofrio, Gail [4 ]
Herring, Andrew A. [1 ,2 ,6 ]
机构
[1] Highland Hosp Alameda Hlth Syst, Dept Emergency Med, Oakland, CA 94602 USA
[2] Highland Hosp Alameda Hlth Syst, Dept Med, Subst Use Disorder Program, Oakland, CA 94602 USA
[3] Highland Hosp Alameda Hlth Syst, Dept Med, Div Primary Care, Oakland, CA 94602 USA
[4] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA
[5] NYU, Ronald O Perelman Dept Emergency Med, Grossman Sch Med, New York, NY USA
[6] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA
关键词
DEPENDENCE;
D O I
10.1016/j.annemergmed.2021.05.013
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: Despite evidence supporting naltrexone as an effective treatment for alcohol use disorder, its use in emergency department (ED) patients has not been described. We implemented a protocol that combined substance use navigation with either oral naltrexone or extended-release intramuscular naltrexone for patients with alcohol use disorder as a strategy to improve follow-up in addiction treatment after ED discharge. Methods: In this descriptive study, we analyzed the results from adult patients discharged from the ED with moderate to severe alcohol use disorder who received either oral naltrexone or extended-release intramuscular naltrexone between May 1, 2020, and October 31, 2020, and assessed their engagement in formal addiction treatment within 30 days after discharge from the ED. Results: Among 59 patients with moderate to severe alcohol use disorder who accepted naltrexone treatment, 41 received oral naltrexone and 18 received extended-release intramuscular naltrexone. The mean (SD) age of the patients was 45.2 (13.4) years; 22 patients (37.3%) were Latinx, 18 (30.5%) were Black, and 16 (27.1%) were White. Among all patients, 9 (15.3%) attended follow-up formal addiction treatment within 30 days after discharge; 5 patients (27.8%) who received extended-release intramuscular naltrexone and 4 patients (9.8%) who received oral naltrexone attended follow-up treatment within 30 days. Conclusion: We implemented a clinical protocol for ED patients with moderate to severe alcohol use disorder using oral naltrexone and extended-release intramuscular naltrexone together with substance use navigation. Identification of alcohol use disorder, a brief intervention, and initiation of naltrexone resulted in a 15% follow-up rate in formal addiction treatment. Future work should prospectively examine the effectiveness of naltrexone as well as the effect of substance use navigation for ED patients with alcohol use disorder.
引用
收藏
页码:752 / 758
页数:7
相关论文
共 50 条
  • [1] Extended-Release Naltrexone and Case Management for Treatment of Alcohol Use Disorder in the Emergency Department
    Murphy, Charles E.
    Coralic, Zlatan
    Wang, Ralph C.
    Montoy, Juan Carlos C.
    Ramirez, Bianca
    Raven, Maria C.
    ANNALS OF EMERGENCY MEDICINE, 2023, 81 (04) : 440 - 449
  • [2] Emergency department-initiated oral naltrexone for patients with moderate to severe alcohol use disorder: A pilot feasibility study
    Cowan, Ethan
    O'Brien-Lambert, Clare
    Eiting, Erick
    Edwards, Bull
    Ryder, Jacqueline
    Calderon, Yvette
    Salsitz, Edwin
    ACADEMIC EMERGENCY MEDICINE, 2025,
  • [3] Extended-release Naltrexone and Case Management for Treatment of Alcohol Used Disorder in the Emergency Department
    Murphy, C.
    Wang, R.
    Montoy, J. C.
    Coralic, Z.
    Ramirez, B.
    Raven, M.
    ANNALS OF EMERGENCY MEDICINE, 2022, 80 (04) : S3 - S3
  • [4] EXTENDED-RELEASE NALTREXONE VERSUS ORAL NALTREXONE FOR ALCOHOL USE DISORDER TREATMENT IN PRIMARY CARE
    Chen, J.
    Obi, R.
    Wong, S.
    Flannery, M.
    McDonald, R.
    Tofighi, B.
    Kermack, A.
    Laska, E.
    Rotrosen, J.
    Gourevitch, M. N.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2016, 40 : 233A - 233A
  • [5] INITIATING EXTENDED-RELEASE NALTREXONE IN FREQUENT EMERGENCY DEPARTMENT USERS WITH SEVERE ALCOHOL USE DISORDERS IS FEASIBLE AND ACCEPTABLE
    McCormack, R. P.
    Gonzalez, M. T.
    Rotrosen, J.
    Gragui, D. A.
    Carmona, R. K.
    Demuth, M. K.
    D'Onofrio, G.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2017, 41 : 144A - 144A
  • [6] Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial
    Korthuis, Philip T.
    Lum, Paula J.
    Vergara-Rodriguez, Pamela
    Ahamad, Keith
    Wood, Evan
    Kunkel, Lynn E.
    Oden, Neal L.
    Lindblad, Robert
    Sorensen, James L.
    Arenas, Virgilio
    Ha, Doan
    Mandler, Raul N.
    McCarty, Dennis
    ADDICTION, 2017, 112 (06) : 1036 - 1044
  • [7] Efficacy of Extended-Release Injectable Naltrexone on Alcohol Use Disorder Treatment: A Systematic Review
    Kedia, Satish K.
    Ahuja, Nikhil
    Dillon, Patrick J.
    Jones, Andrew
    Kumar, Santosh
    Satapathy, Sanjaya
    JOURNAL OF PSYCHOACTIVE DRUGS, 2023, 55 (02) : 233 - 245
  • [8] EXTENDED-RELEASE NALTREXONE WAS FEASIBLE, ACCEPTABLE, AND REDUCED DRINKING IN PATIENTS WITH ALCOHOL USE DISORDERS WHO FREQUENT THE EMERGENCY DEPARTMENT
    McCormack, R. P.
    Rotrosen, J.
    Wall, S. P.
    Moran, Z.
    Goldfrank, L.
    Lee, J.
    Doran, K. M.
    Shin, S.
    D'Onofrio, G.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2020, 44 : 158 - 158
  • [9] Impact of hospital-administered extended-release naltrexone on readmission rates for patients with alcohol use disorder
    Singh, Nathaniel M.
    Daniel, Kristin
    Balasanova, Alena A.
    INTERNAL MEDICINE JOURNAL, 2024, 54 (10) : 1644 - 1651
  • [10] Extended-release Naltrexone Is Not Linked to Hepatotoxicity in Adults Experiencing Homelessness and Alcohol Use Disorder
    Vutien, Philip
    Kim, Nicole J.
    Merrill, Joseph O.
    Duncan, Mark H.
    Ioannou, George N.
    Collins, Susan E.
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (03) : 363 - 366